Electrocardiographic and hematological changes by exercise test in coronary patients and pyridinolcarbamate pretreatment. A double-blind crossover trial.

Abstract Forty hospitalized patients with angina pectoris, 25 men and 15 women, 37 to 75 years of age, were subjected to Master's two-step test. Three hours before the test, 1.0 Gm. of pyridinolcarbamate or placebo was given orally using a double-blind technique. Before, immediately after, and 3, 5, 7, 10, and 30 minutes after exercise, electrocardiographic changes and clinical symptoms were observed. In 20 of the above subjects prothrombin activity, calcium clotting time, and the platelet and adhesive platelet count was measured. Thirty-three of the 40 patients pretreated with placebo developed ischemic ECG findings immediately to 10 minutes after the exercise test. Seventeen of the same 40 subjects pretreated with pyridinolcarbamate developed ischemic ECG findings. The difference between placebo and pyridinolcarbamate was statistically significant at p For the second exercise test the 17 patients who had received pyridinolcarbamate for the first test were pretreated with placebo, and 13 showed positive ischemic ECG changes. The 23 patients who had received placebo for the first exercise test were pretreated for the second test with pyridinolcarbamate, and 10 developed positive ECG changes. There was no significant difference noted between the two exercise tests in regard to the appearance of ischemic ECG changes. The appearance of anginal pain after exercise was prevented by pretreatment with pyridinolcarbamate (p In comparison to other 39 healthy volunteers, the patients with angina pectoris showed enhanced blood coagulability and lower platelet count. In healthy persons, enhanced blood coagulability was observed one minute after the exercise test (p p